TNGX Similar Chart Price Prediction
The price of TNGX is predicted to go up -5.56%, based on the high correlation periods with AVAL. The similarity of these two price pattern on the periods is 95.46%.
TNGX
AVAL
Down: -5.56%Similarity: 95.46%
TNGX Revenue Forecast
TNGX EPS Forecast
TNGX FAQs
What is bull’s view on TNGX?
What is bear's view on TNGX?
What is TNGX revenue forecast for next quarter？
What is TNGX eps forecast for next quarter？
TNGX Analyst's Forecast
Yuan Zhi
B. Riley Securities
Strong Buy
2024-11-11
Price Target
$16 → $8
Upside
+136.69%
B. Riley lowered the firm's price target on Tango Therapeutics to $8 from $16 and keeps a Buy rating on the shares. Tango reported highly anticipated results for their Phase I MTA-cooperative PRMT5 inhibitor programs, brain penetrant TNG908 and potentially best-in-class TNG462, and while TNG908 is active but not competitive, TNG908 development will be discontinued, the analyst tells investors in a research note. Tango Therapeutics is in the penalty box, as investors are losing patience and are disappointed to learn TNG908 has limited efficacy in Glioblastoma Multiforme after the trial has been running for 2.5 years, and TNG462 data remains preliminary and incomplete, the firm says, but there are silver linings that give it confidence that there is a turnaround story in play.
